Mucin characteristics dictate that the nature of immune response required to address the recognition and subsequent lyses of mucin-expressing

tumours should follow a MHC-unrestricted αβ TCR-mediated effector cell response [34, 68]. Frequent loss of DC maturation and ineffective MUC-1 processing qualitatively restricts MHC-dependent recognition and lysis of tumour cells. MUC-1, by far the most ubiquously expressed TAA, plays an important role in providing molecular targets for immune system tumour recognition [31, 35]. Prostate metastatic cancers that lack HLA class I expression are recognized and lysed by CD8+ CD56− T cells and CD8+ CD56+ natural killer T (NKT) cells in a manner that needs synergistic action of tumour-specific MUC-1, IL2 and IL12 and needs no MHC class I and CD1 expression [69]. HLA-unrestricted CTL recognition of tumour-associated learn more epitopes of MUC-1 involves selleck kinase inhibitor TCR αβ, CD3 and CD8

and not the HLA type [70, 71], suggesting that expression of underglycosylated MUC-1 exposes highly antigenic repetitive multiple epitopes on the peptide core that crosslinks and aggregates TCR on the mucin-specific T cells [70, 71]. Both CD4+ and CD8+ T cells recognize MUC-1 epitopes in an HLA-unrestricted manner and produce appropriate responses [72]. Presence of low level of MUC-1 antibodies in the normal individuals suggests that precursors of HLA-unrestricted anti-MUC-1 CD4+ T cells already exist in the peripheral blood and get activated Orotidine 5′-phosphate decarboxylase once MUC-1 is overexpressed in cancers [33]. Despite numerous investigations, the exact role of mucins in immune regulation is not fully elucidated, partly due to diversity of mucin molecules and heterogeneity in functions. Attempts using MUC-1-dependent vaccines evolved over the years with the advent of knowledge on tumour immunomodulation by mucins and by the partial clinical failures associated with the development of tolerance. From simple MUC-1-immunodominant peptide or variable repeat (VNTR)

vaccines it has graduated to employ recombinant mucin peptides engineered with glycomoieties, mannan-MUC-1 fusion protein (MFP)-pulsed dendritic cell-based vaccines (to activate T cells), and MUC-1 tripatriate vaccines, having multiple components such as immunoadjuvant Pam3CysSK4, a peptide Thelper epitope and an aberrantly glycosylated MUC-1 peptide, MUC-1+/CEA+ tumour cell – DC fusion vaccines (for CTL induction), synthetic multimeric Tn/STn MUC-1 glycopeptides (to override tolerance) or MUC-6-Tn glycoconjugates, and adaptive and passive immunization protocols employing ex-vivo expanded tumour-specific T cells exposed to MUC-1 peptides/MUC-1-expressing cell lines.